Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population

被引:29
|
作者
Wang, LZ
Sato, K
Tsuchiya, N
Yu, JG
Ohyama, C
Satoh, S
Habuchi, T
Ogawa, O
Kato, T
机构
[1] Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan
关键词
gene polymorphisms; Caucasian populations; prostate cancer;
D O I
10.1016/j.canlet.2003.08.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies have indicated that the prostate-specific antigen (PSA) gene polymorphisms may be associated with the risk of prostate cancer in Caucasian populations. To verify the association, we examined the PSA polymorphisms at positions - 158 and - 252 in 300 prostate cancer cases, 216 benign prostatic hyperplasia (BPH) cases, and 266 controls by the PCR-restriction fragment length polymorphism analysis. Regarding the PSA polymorphism at position - 158, the A allele was less common in the Japanese population (A 0.22, G 0.78) than that in other ethnic populations (A 0.37-0.52, G 0.48-0.63). No significant associations were found between the polymorphism and the risks of prostate cancer (P = 0.530) and BPH (P = 0.740) and between the polymorphism, and the serum PSA level (P = 0.626). As for the polymorphism at position - 252, no significant results were also found. In conclusion, the PSA polymorphisms may not be associated with the risk of prostate cancer development and its disease progression and the risk of BPH in Japanese men, and may also be not related to the serum PSA level in Japanese men with prostate cancer. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [41] Prostate-specific antigen velocity (PSAV): a practical role for PSA?
    Thanigasalam, Ruban
    Mancuso, Pascal
    Tsao, Kim
    Rashid, Prem
    ANZ JOURNAL OF SURGERY, 2009, 79 (10) : 703 - 706
  • [42] Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis
    Boyle, Peter
    Koechlin, Alice
    Bota, Maria
    d'Onofrio, Alberto
    Zaridze, David G.
    Perrin, Paul
    Fitzpatrick, John
    Burnett, Arthur L.
    Boniol, Mathieu
    BJU INTERNATIONAL, 2016, 118 (05) : 731 - 741
  • [43] Algorithms based on prostate-specific antigen (PSA), free psa, digital rectal examination and prostate volume reduce false-postitive psa results in prostate cancer screening
    Finne, P
    Finne, R
    Bangma, C
    Hugosson, J
    Hakama, M
    Auvinen, A
    Stenman, UH
    INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) : 310 - 315
  • [44] Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
    Sushentsev, Nikita
    Abrego, Luis
    Colarieti, Anna
    Sanmugalingam, Nimalan
    Stanzione, Arnaldo
    Zawaideh, Jeries Paolo
    Caglic, Iztok
    Zaikin, Alexey
    Blyuss, Oleg
    Barrett, Tristan
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 36 - 39
  • [45] Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (γ-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels
    Kurita, Y
    Terada, H
    Masuda, H
    Suzuki, K
    Fujita, K
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (02): : 224 - 230
  • [46] Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk
    Bonn, Stephanie E.
    Sjolander, Arvid
    Tillander, Annika
    Wiklund, Fredrik
    Gronberg, Henrik
    Balter, Katarina
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 50 - 57
  • [47] Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation
    Schaefer, U
    Witt, F
    Schueller, P
    Micke, O
    Willich, N
    ANTICANCER RESEARCH, 2000, 20 (6D) : 4989 - 4992
  • [48] Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels
    Furuya, Y
    Ohta, S
    Sato, N
    Kotake, T
    Sugano, I
    Nagao, K
    Masai, M
    ANTICANCER RESEARCH, 2001, 21 (2B) : 1317 - 1320
  • [49] Prostate specific antigen (PSA) as a predictor of biological behavior of prostate cancer
    Shohab, Durre
    Khawaja, Athar
    Jamil, Imran
    Rehman, Asadur
    Akhter, Saeed
    RAWAL MEDICAL JOURNAL, 2014, 39 (04): : 425 - 427
  • [50] Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
    D'Amico, Anthony V.
    McLeod, David G.
    Carroll, Peter R.
    Cullen, Jennifer
    Chen, Ming-Hui
    CANCER, 2007, 109 (07) : 1290 - 1295